Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma

作     者：Alvin Ho-Kwan Cheung Colin Siu-Chi Lam Henry Shiu-Cheung Tam Tan-To Cheung Roberta Pang Ronnie Tung-Ping Poon 

作者机构：Department of Surgery University of Hong Kong and Queen Mary Hospital 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2016年第15卷第5期

页      面：493-498页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：University of Hong Kong  HKU 

主　　题：doxorubicin-eluting beads transarterial chemoembolization hepatocellular carcinoma 

摘      要：BACKGROUND: Chemoembolization with doxorubucin-eluting beads (DEB) has been used to treat hepatocellular carcinoma (HCC) since 2007. This study compared the efifcacy and sur-vival between transarterial chemoembolization (TACE) with DEB and conventional approach (cTACE) in HCC treatment. METHODS: This retrospective case-control study compared the overall survival and tumor response of HCC patients to cTACE (n=190) and DEB (n=143) by the reassessment of com-puted tomography and serum alpha-fetoprotein (AFP). Mul-tivariate analysis was used to determine the factors affecting tumor response. RESULTS: The median post-treatment to pre-treatment AFP level was 0.8 for a DEB session (n=258) and 1.0 for a cTACE session (n=452), showing a signiifcantly greater decrease in AFP after DEB (P80 months after the ifrst TACE session in the DEB group. CONCLUSION: DEB is a safe alternative to cTACE in HCC pa-tients with better therapeutic efifcacy.